Wednesday, June 24, 2020, 12:00 AM - Wednesday, June 23, 2021, 11:00 PM


COVID - 19 is a novel viral infection, this presentation will discuss what is currently known about the efficacy and safety of experimental and supportive drug treatments for COVID - 19. It will summarize emerging evidence for experimental and adjunctive therapies and practical considerations for the front line clinician.

1. Identify emerging medical literature describing pharmacotherapy treatments and outcomes of experimental COVID - 19 therapy as well as safety and access considerations.

Complimentary to all SHC employees.

ANCC - American Nurses Credentialing Center contact hour(s) (1.00 hours), General Attendance (1.00 hours), CA BRN - California Board of Registered Nurses contact hour(s) (1.00 hours)

Stanford Health Care is provider approved by the California Board of Registered Nursing (BRN).  Provider Number CEP12165.

Stanford Health Care Center for Education and Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Neither SHC nor ANCC endorse any commercial products

2020 by Stanford Health Care, Division of Patient Care Services.
All rights reserved. No audio or video taping allowed. We reserve the right to make program changes. All students must be registered, attend the entire course, and submit an evaluation after course completion to earn credit hours.

The registration form for this activity Is currently unavailable.